The momentum became even more apparent when Eli Lilly disclosed plans to acquire AtaiBeckley for up to $3.8 billion, largely to obtain BPL-003, an intranasal formulation of synthetic 5-MeO-DMT. By contrast, inhaled synthetic 5-MeO-DMT produces an intense but remarkably brief psychedelic experience, usually lasting only 15 to 30 minutes. One challenge is that psychedelic trials are inherently difficult to blind. Synthetic 5-MeO-DMT has now crossed that threshold. The conversation has shifted from folklore to pharmacology, from anecdote to randomized clinical trials, and from curiosity to one of the most closely watched programs in modern neuropsychopharmacology.